Following participation in this educational activity, hematologists/oncologists, nurses, pharmacists, cell therapy experts, and other HCPs actively involved in the care of patients with multiple myeloma should be better able to:
- Describe the differences in product composition and toxicity burden between existing and emerging CAR T-cell therapies for multiple myeloma.
- Use recent clinical trial data to guide strategies for selecting and sequencing CAR T-cell therapy in patients with relapsed or refractory multiple myeloma.
- Identify unique toxicities associated with CAR T-cell therapies and tailor strategies to reduce toxicity burden in order to ensure patient safety and optimize outcomes.
- Improve patient-centered care and outcomes by implementing effective strategies for shared decision-making and communication.